Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy (SMA) is the most common genetic disease leading to infant mortality. This neuromuscular disorder is caused by the loss or mutation of the telomeric copy of the 'survival of motor neuron' (Smn) gene, termed SMN1. Loss of SMN1 leads to reduced SMN protein levels, inducing degeneration of motor neurons (MN) and progressive muscle weakness and atrophy. To date, SMA remains incurable due to the lack of a method to deliver therapeutically active molecules to the spinal cord. Gene therapy, consisting of reintroducing SMN1 in MNs, is an attractive approach for SMA. Here we used postnatal day 1 systemic injection of self-complementary adeno-associated virus (scAAV9) vectors carrying a codon-optimized SMN1 sequence and a chimeric intron placed downstream of the strong phosphoglycerate kinase (PGK) promoter (SMNopti) to overexpress the human SMN protein in a mouse model of severe SMA. Survival analysis showed that this treatment rescued 100% of the mice, increasing life expectancy from 27 to over 340 days (median survival of 199 days) in mice that normally survive about 13 days. The systemic scAAV9 therapy mediated complete correction of motor function, prevented MN death and rescued the weight loss phenotype close to normal. This study reports the most efficient rescue of SMA mice to date after a single intravenous injection of an optimized SMN-encoding scAAV9, highlighting the considerable potential of this method for the treatment of human SMA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies, delivering scAAV9-SMN to SMA pups, demonstrated positive effects on survival, growth, and neuromuscular transmission.11,12”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [12]
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedIdentification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990 · cited 1×
“The gene responsible for the most common form of SMA was identified in 1995 and named ‘survival motor neuron’ (Smn) (2).”
BackgroundIntravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 1×
“An independent study similarly demonstrated the high potential of self-complementary AAV of serotype 9 (scAAV9) for neuronal transduction, albeit only in neonatal mice (9).”
Lambrechts, D., Storkebaum, E., Morimoto, M., Del-Favero, J., Desmet, F., Marklund, S. L., Wyns, S., Thijs, V., Andersson, J., van Marion, I., et al. (2003) · Nature Genetics · doi:10.1038/ng1211 · Cited by 860
Monani, U. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.3.333 · Cited by 729
Neuroblastoma × spinal cord (NSC) hybrid cell lines resemble developing motor neurons
Cashman, N. R., Durham, H. D., Blusztajn, J. K., Oda, K., Tabira, T., Shaw, I. T., Dahrouge, S., & Antel, J. P. (1992) · Developmental Dynamics · doi:10.1002/aja.1001940306 · Cited by 722
Introns increase transcriptional efficiency in transgenic mice.
Brinster, R. L., Allen, J. M., Behringer, R. R., Gelinas, R. E., & Palmiter, R. D. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.3.836 · Cited by 722 · cited 1×
“Heterologous introns have been indeed reported to improve gene expression, by influencing transcriptional initiation or elongation (via enhancers or other cis-acting elements), by enhancing mRNA stability in the nucleus (via the process of mRNA splicing), or by facilitating opening of chromosomal domains (13,14) The P…”
BackgroundA mouse model for spinal muscular atrophy
Hsieh-Li, H. M., Chang, J.-G., Jong, Y.-J., Wu, M.-H., Wang, N. M., Tsai, C. H., & Li, H. (2000) · Nature Genetics · doi:10.1038/71709 · Cited by 702
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664 · cited 1×
“Moreover, this pathological feature was observed from 3 to 4 weeks of age in the scAAV9-SMNopti treated severe SMA mice, similarly to what was recently described after antisense correction of SMN2 splicing in a mild SMA model (42).”
BackgroundHerzog, E., Bellenchi, G. C., Gras, C., Bernard, V., Ravassard, P., Bedet, C., Gasnier, B., Giros, B., & El Mestikawy, S. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-22-j0001.2001 · Cited by 625 · cited 1×
“ISHs were performed as previously described (50,51)) on 14 mm thick serial sections of cervical spinal cord.”
MethodSelf-citationLe, T. T., Pham, L. T., Butchbach, M. E. R., Zhang, H. L., Monani, U. R., Coovert, D. D., Gavrilina, T. O., Xing, L., Bassell, G. J., & Burghes, A. H. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi078 · Cited by 598
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 2×
“Interestingly, adeno-associated virus (AAV) vectors based on a double-stranded genome were demonstrated to have the general ability to bypass the step of second-strand DNA synthesis mediated by the host cells, achieving a greater and faster transgene expression compared with single-stranded AAV vectors, offering new p…”
BackgroundDuque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511
Self-citationHeterologous introns can enhance expression of transgenes in mice.
Palmiter, R. D., Sandgren, E. P., Avarbock, M. R., Allen, D. D., & Brinster, R. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.478 · Cited by 484 · cited 1×
“Heterologous introns have been indeed reported to improve gene expression, by influencing transcriptional initiation or elongation (via enhancers or other cis-acting elements), by enhancing mRNA stability in the nucleus (via the process of mRNA splicing), or by facilitating opening of chromosomal domains (13,14) The P…”
BackgroundA Calcium-Dependent Feedback Mechanism Participates in Shaping Single NMDA Miniature EPSCs
Umemiya, M., Chen, N., Raymond, L. A., & Murphy, T. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00001.2001 · Cited by 450
Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
Mailman, M. D., Heinz, J. W., Papp, A. C., Snyder, P. J., Sedra, M. S., Wirth, B., Burghes, A. H. M., & Prior, T. W. (2002) · Genetics in Medicine · doi:10.1097/00125817-200201000-00004 · Cited by 364 · cited 3×
“Homozygous disruption (by deletion, conversion or mutation) of the telomeric copy of Smn, termed SMN1, leads to decreased levels of full-length SMN protein (FL-SMN) in MNs (3).”
BackgroundSpinal Muscular Atrophy: A Deficiency in a Ubiquitous Protein; a Motor Neuron-Specific Disease
Monani, U. R. (2005) · Neuron · doi:10.1016/j.neuron.2005.12.001 · Cited by 350 · cited 2×
“The centromeric copy, SMN2, critically differs from SMN1 by a C–T nucleotide transition in exon 7 thereby promoting exon skipping during alternative splicing (3).”
BackgroundPassini, M. A., Bu, J., Roskelley, E. M., Richards, A. M., Sardi, S. P., O’Riordan, C. R., Klinger, K. W., Shihabuddin, L. S., & Cheng, S. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41615 · Cited by 292 · cited 5×
“However, as demonstrated after AAV8-SMN injections into the CNS (27), and as suggested in several previous studies (34–36), the therapeutic effect of SMN overexpression in SMA mice could also result from axonal sprouting and remodeling of the neuromuscular junction (NMJ).”
BackgroundInfluentialDeglon, N., Tseng, J. L., Bensadoun, J.-C., Zurn, A. D., Arsenijevic, Y., Almeida, L. P. D., Zufferey, R., Trono, D., & Aebischer, P. (2000) · Human Gene Therapy · doi:10.1089/10430340050016256 · Cited by 292 · cited 1×
“In the CNS, a lentiviral vector expressing lacZ under control of the PGK promoter was shown to drive in vivo expression preferentially in neurons (17).”
BackgroundSystemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy
Valori, C. F., Ning, K., Wyles, M., Mead, R. J., Grierson, A. J., Shaw, P. J., & Azzouz, M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000830 · Cited by 285 · cited 4×
“Recently, the high potential of scAAV9 vectors for systemic gene therapy of SMA has been similarly reported in two independent studies (32,33).”
BackgroundMethodResultInfluentialDeletion of Murine SMN Exon 7 Directed to Skeletal Muscle Leads to Severe Muscular Dystrophy
Cifuentes-Diaz, C., Frugier, T., Tiziano, F. D., Lacène, E., Roblot, N., Joshi, V., Moreau, M. H., & Melki, J. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.5.1107 · Cited by 240
SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy
Riessland, M., Ackermann, B., Förster, A., Jakubik, M., Hauke, J., Garbes, L., Fritzsche, I., Mende, Y., Blumcke, I., Hahnen, E., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq023 · Cited by 220
Gavrilina, T. O., McGovern, V. L., Workman, E., Crawford, T. O., Gogliotti, R. G., DiDonato, C. J., Monani, U. R., Morris, G. E., & Burghes, A. H. M. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm379 · Cited by 212 · cited 1×
“Although CNS-directed SMN expression has been reported to be highly efficient in ameliorating SMA-associated manifestations in transgenic mice (26,27), post-natal expression of SMN in non-nervous tissues (such as muscle or liver) may also play an important role in SMA pathogenesis (28–31).”
BackgroundLentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy
Azzouz, M., Le, T., Ralph, G. S., Walmsley, L., Monani, U. R., Lee, D. C. P., Wilkes, F., Mitrophanous, K. A., Kingsman, S. M., Burghes, A. H. M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422922 · Cited by 209 · cited 3×
“These results far exceeded the therapeutic improvement described in previous studies based on pharmacological or RNA transplicing approaches (23–25), as well as that of a previous gene therapy study using multiple intramuscular lentivirus injections (5).”
BackgroundResultInfluentialBevan, A. K., Hutchinson, K. R., Foust, K. D., Braun, L., McGovern, V. L., Schmelzer, L., Ward, J. G., Petruska, J. C., Lucchesi, P. A., Burghes, A. H. M., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq300 · Cited by 209
Recombinant AAV-mediated gene delivery to the central nervous system
Tenenbaum, L., Chtarto, A., Lehtonen, E., Velu, T., Brotchi, J., & Levivier, M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.506 · Cited by 204 · cited 1×
“In particular, the stability of PGK-driven expression of transgenes confers to this promoter a great advantage over the cytomegalovirus promoter whose transcriptional activity has been reported to significantly decrease with time (16).”
BackgroundZhang, H., Xing, L., Rossoll, W., Wichterle, H., Singer, R. H., & Bassell, G. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3967-05.2006 · Cited by 200
Sopher, B. L., Thomas, P. S., LaFevre-Bernt, M. A., Holm, I. E., Wilke, S. A., Ware, C. B., Jin, L.-W., Libby, R. T., Ellerby, L. M., & La Spada, A. R. (2004) · Neuron · doi:10.1016/s0896-6273(04)00082-0 · Cited by 191
Deml, L., Bojak, A., Steck, S., Graf, M., Wild, J., Schirmbeck, R., Wolf, H., & Wagner, R. (2001) · Journal of Virology · doi:10.1128/jvi.75.22.10991-11001.2001 · Cited by 187
Monani, U. R., Pastore, M., Gavrilina, T. O., Jablonka, S., Le, T. T., Andreassi, C., DiCocco, J. M., Lorson, C. L., Androphy, E. J., Sendtner, M., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208079 · Cited by 185
Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model
Bowerman, M., Beauvais, A., Anderson, C. L., & Kothary, R. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq021 · Cited by 177
The Genetic Component in Child Mortality
Roberts, D. F., Chavez, J., & Court, S. D. M. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.239.33 · Cited by 173 · cited 1×
“With no effective treatment currently available, SMA remains the leading genetic cause of infant mortality (1).”
BackgroundSMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy
Wishart, T. M., Huang, J. P.-W., Murray, L. M., Lamont, D. J., Mutsaers, C. A., Ross, J., Geldsetzer, P., Ansorge, O., Talbot, K., Parson, S. H., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq340 · Cited by 159 · cited 1×
“This could explain the behavioral disturbances (notably the hyperactivity) observed in some treated SMNdelta7 mice after 40 days of age, possibly due to regional changes in brain morphology as recently reported in SMA mice (22).”
BackgroundRajendra, T. K., Gonsalvez, G. B., Walker, M. P., Shpargel, K. B., Salz, H. K., & Matera, A. G. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200610053 · Cited by 156
Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition
Narver, H. L., Kong, L., Burnett, B. G., Choe, D. W., Bosch‐Marcé, M., Taye, A. A., Eckhaus, M. A., & Sumner, C. J. (2008) · Annals of Neurology · doi:10.1002/ana.21449 · Cited by 152
Vascular Perfusion Abnormalities in Infants with Spinal Muscular Atrophy
Araújo, A. P. D. Q. C., Araújo, M. L. C., & Swoboda, K. J. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.01.071 · Cited by 140
Digital necroses and vascular thrombosis in severe spinal muscular atrophy
Rudnik‐Schöneborn, S., Vogelgesang, S., Armbrust, S., Graul-Neumann, L. M., Fusch, C., & Zerres, K. (2010) · Muscle & Nerve · doi:10.1002/mus.21654 · Cited by 126 · cited 2×
“Although the clear cause of these symptoms has not yet been identified, digital necrosis was reported to be due to insufficient vascular perfusion (43,44).”
BackgroundRefined Characterization of the Expression and Stability of the SMN Gene Products
Vitte, J., Fassier, C., Tiziano, F. D., Dalard, C., Soave, S., Roblot, N., Brahe, C., Saugier-Véber, P., Bonnefont, J., & Melki, J. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070399 · Cited by 112
Trans-Splicing-Mediated Improvement in a Severe Mouse Model of Spinal Muscular Atrophy
Coady, T. H., & Lorson, C. L. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4489-09.2010 · Cited by 95
Régulier, E., Schneider, B. L., Déglon, N., Beuzard, Y., & Aebischer, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300687 · Cited by 90 · cited 1×
“Heterologous introns have been indeed reported to improve gene expression, by influencing transcriptional initiation or elongation (via enhancers or other cis-acting elements), by enhancing mRNA stability in the nucleus (via the process of mRNA splicing), or by facilitating opening of chromosomal domains (13,14) The P…”
BackgroundSetola, V., Terao, M., Locatelli, D., Bassanini, S., Garattini, E., & Battaglia, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610660104 · Cited by 78
Stratigopoulos, G., Lanzano, P., Deng, L., Guo, J., Kaufmann, P., Darras, B. T., Finkel, R. S., Tawil, R., McDermott, M., Martens, W. B., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.239 · Cited by 78 · cited 1×
“Indeed plastin 3 expression has been associated with disease severity only in postpubertal females (38).”
BackgroundWaldman, Y. Y., Tuller, T., Shlomi, T., Sharan, R., & Ruppin, E. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq009 · Cited by 76
Younan, C., Mitchell, P. L. R., Cumming, R. G., Rochtchina, E., Panchapakesan, J., & Tumuluri, K. (2003) · Ophthalmic Epidemiology · doi:10.1076/opep.10.4.227.15905 · Cited by 69 · cited 1×
“Although additional work is necessary to determine the cause of this pathological feature, a role of vascular perfusion abnormalities could also be considered (48).”
BackgroundThe spinal muscular atrophy gene product regulates neurite outgrowth: importance of the C terminus
van Bergeijk, J., Rydel‐Könecke, K., Grothe, C., & Claus, P. (2007) · The FASEB Journal · doi:10.1096/fj.06-7136com · Cited by 62
Establishing a standardized therapeutic testing protocol for spinal muscular atrophy
Tsai, L.-K., Tsai, M.-S., Lin, T.-B., Hwu, W.-L., & Li, H. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.07.004 · Cited by 58
Possible pathogenic role of muscle cell dysfunction in motor neuron death in spinal muscular atrophy
Guettier‐Sigrist, S., Hugel, B., Coupin, G., Freyssinet, J., Poindron, P., & Warter, J. (2002) · Muscle & Nerve · doi:10.1002/mus.10081 · Cited by 51
Ravassard, P., Chatail, F., Mallet, J., & Icard-Liepkalns, C. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19970415)48:2<146::aid-jnr7>3.0.co;2-c · Cited by 41 · cited 1×
“ISHs were performed as previously described (50,51)) on 14 mm thick serial sections of cervical spinal cord.”
MethodSelf-citationCodon optimization improves heterologous expression of a Schistosoma mansoni cDNA in HEK293 cells
Hamdan, F. F., Mousa, A., & Ribeiro, P. (2002) · Parasitology Research · doi:10.1007/s00436-001-0585-0 · Cited by 40
Chronic from of childhood spinal muscular atrophy
Hausmanowa-Petrusewicz, I., Zaremba, J., & Borkowska, J. (1979) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(79)90124-2 · Cited by 20
Spinal muscular atrophy, Dandy-Walker complex, and cataracts in two siblings: a new entity?
Πάνας, Μ., Spengos, K. M., Tsivgoulis, G., Kalfakis, N., Sfagos, C., Vassilopoulos, D., & Markomichelakis, N. N. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.055855 · Cited by 7
Cited by
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Preclinical studies, delivering scAAV9-SMN to SMA pups, demonstrated positive effects on survival, growth, and neuromuscular transmission.(11,12) Two key observations from these studies worth noting were both time of intervention and dose response effects on survival.”
BackgroundHua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Kolb, S. J., & Kissel, J. T. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.004 · Cited by 603
Metadata
- Authors
- Dominguez, E., Marais, T., Chatauret, N., Benkhelifa-Ziyyat, S., Duque, S., Ravassard, P., Carcenac, R., Astord, S., de Moura, A. P., Voit, T., & Barkats, M.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Barkats, Martine
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-30
- Volume
- 20
- Issue
- 4
- Pages
- 681-693
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2119878613
- Cited by
- 298
- References
- 52
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 11 · 2023: 10 · 2022: 8 · 2021: 17 · 2020: 17 · 2019: 17 · 2018: 15 · 2017: 21 · 2016: 21 · 2015: 31 · 2014: 29 · 2013: 33 · 2012: 23
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- California Department of Transportation
- National Science Council
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy, SMN1, gene therapy, codon optimization, intravenous delivery, motor neuron survival, phosphoglycerate kinase promoter, SMA mouse model
- MeSH terms
- Dependovirus, Animals, Disease Models, Animal, Female, Genetic Vectors, Humans, Motor Neurons, Muscular Atrophy, Spinal, Phenotype, Spinal Cord, Genetic Therapy, Survival Analysis, Treatment Outcome, Gene Transfer Techniques, Mice, Knockout, Mice, Survival of Motor Neuron 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.